Indegene Limited — M&A Activity 2025

Oct 1, 2025

INDGN/SE/2025-26/59

==> picture [77 x 77] intentionally omitted <==

October 1, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Company’s wholly owned subsidiary, Indegene Ireland Limited has, on September 30, 2025, signed a Share Purchase Agreement (“SPA”) to acquire 100% equity shares in BioPharm Parent Holding, Inc. along with its subsidiaries (collectively, BioPharm) for an amount not exceeding USD 106 Million, subject to cash/net working capital adjustments.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/ 2023/123 dated July 13, 2023, are provided below as Annexure.

The above information is being made available on the website of the Company https://www.indegene.com/.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

Srishti Digitally signed by Srishti Ramesh Ramesh Kaushik Kaushik Date: 2025.10.01 14:20:49 +05'30'

Srishti Ramesh Kaushik

Company Secretary and Compliance Officer

Enclosed: as above

==> picture [132 x 41] intentionally omitted <==

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy

Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: L73100KA1998PLC102040

Annexure

==> picture [77 x 77] intentionally omitted <==

Sr. No.	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.;	BioPharm Parent Holding, Inc. along with its subsidiaries (collectively “BioPharm”) provides data-driven healthcare provider marketing solutions for Life Sciences clients BioPharm is headquartered in New Hope, Pennsylvania, USA, and has over 90 employees all based out of the USA. BioPharm reported revenues of USD 38.13 Million (unaudited) in the financial year ending December 2024
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No. The transaction does not fall within the related party transaction and no~~promoter / promoter group /~~group companies have any interest in the entity being acquired
3.	Industry to which the entity being acquired belongs	Marketing and Communications Agency
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To further augment Indegene's capabilities and offerings in omnichannel marketing agency business
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6.	Indicative time period for completion of the acquisition	1stOctober 2025
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	All-cash transaction with deferred performance / milestone-based consideration.

==> picture [132 x 41] intentionally omitted <==

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy

Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: L73100KA1998PLC102040

8.	Cost of acquisition or the price at which the shares are acquired	Total purchase consideration amount not exceeding USD 106 Millionsubject to cash/net working capital adjustments.
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	BioPharm provides marketing and communications solutions to Life Sciences clients in the North American region. Date of incorporation: 27 August 2014 Turnover of BioPharm for the following financial years, ending December: 2022: USD 40.89 Million (unaudited) 2023: USD 35.97 Million (unaudited) 2024: USD 38.13 Million (unaudited)

==> picture [132 x 41] intentionally omitted <==

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: L73100KA1998PLC102040